CD19 and B-cell non-Hodgkin lymphoma: Since that time, additional pivotal trials evaluating 2nd generation CD-19 CAR-T products for B-cell lymphoma have led to three more FDA approvals, including tisagenlecleucel in 2018 [5], brexucabtagene autoleucel in 2020 [6] and lisocabtagene maraleucel in 2021 [7].